Latest Biotech News

Biopharma finance activity picked up in Q1 2026, with total financings reaching $22.82 billion—up about 74% year over year—signaling a stronger start for public-market and late-stage funding. The...

The FDA denied Harrison.ai’s petition seeking a partial 510(k) exemption for certain diagnostic and detection AI devices. The agency’s decision maintains the existing premarket review pathway...

AbbVie sued the federal government over the 340B program, arguing the interpretation of the word “patient” in the program should be revisited. The filing comes as the 340B discount framework...

23andMe reported genetic associations tied to how patients respond to GLP-1 receptor agonists, identifying variants that map to pharmacodynamic target genes. In a Nature study, investigators...

Cure or control strategies for difficult cancers remained active as clinical-stage and translational programs pushed forward. In glioblastoma, GLORIA trial results combine an L-RNA aptamer...

Waters received FDA 510(k) clearance for its BD Onclarity HPV self-collection kit and assay, enabling an at-home screening workflow for high-risk HPV detection. The company said the cleared...

Seer said it will support the PRECISE-SG100K initiative by profiling plasma proteomes for roughly 10,000 participants using its Proteograph platform. The workflow will be combined with data from...

A surge in March dealmaking underlined expectations for 2026’s merger cycle, with analysts tracking seven transactions worth more than $1 billion in a 12-day period. The reported headline value...

Biopharma M&A activity surged in March 2026, with big pharma buyers completing seven transactions worth more than $1 billion each across a 12-day stretch, according to deal tracking summarized in...

Roche escalated its degrader strategy with a new collaboration with C4 Therapeutics focused on degrader-antibody conjugates (DACs), combining C4’s targeted protein degradation payloads with...

Gilead exercised a $45 million option on Kymera Therapeutics’ preclinical molecular-glue degrader program, positioning the company to advance an oral CDK2 degrader into IND-enabling work. Under...

Tempus and Gilead expanded their data partnership, giving Gilead broader access to Tempus’ multimodal real-world cancer datasets and the Tempus AI platform. The update builds on an existing deal...

The FDA denied a petition from Harrison.ai seeking partial exemption from premarket review for certain diagnostic and detection AI devices, provided the manufacturer has 510(k) clearance for a...

Endospan received U.S. premarket approval for its Nexus aortic arch stent graft, bringing the company closer to its planned acquisition by Artivion. The agreement gives Artivion an option to...

Biotech financing activity is rebounding early in 2026, with total biopharma financings reaching $22.82 billion in Q1 2026, up about 74% from $13.12 billion in Q1 2025 but down 31% from the $33.16...

Life Biosciences advanced its clinical epigenetic reprogramming program after raising a fully subscribed $80 million Series D. The funding supports ER-100, which is in phase I trials testing the...

Researchers at the Terasaki Institute for Biomedical Innovation reported a smart polymer contact lens that measures intraocular pressure (IOP) in real time and automatically releases therapy when...

Ibio received key regulatory authorizations in Australia to initiate a first-in-human trial for IBIO-600, its obesity candidate. The Therapeutic Goods Administration (TGA) acknowledged the...

A Nature Communications study mapped how tau species evolve in both plasma and cerebrospinal fluid (CSF) during Alzheimer’s disease progression, providing new “trajectories” for biomarkers rather...

University of Virginia researchers unveiled YuelDesign, YuelPocket and YuelBond, a set of AI tools that use diffusion models to generate drug-like molecules tailored to specific protein...